Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 23;14(3):e084412.
doi: 10.1136/bmjopen-2024-084412.

Prostate Cancer Survivorship Essentials for men with prostate cancer on androgen deprivation therapy: protocol for a randomised controlled trial of a tele-based nurse-led survivorship care intervention (PCEssentials Hormone Therapy Study)

Anna Green  1 , Robert U Newton  2 , David P Smith  3 , Haitham Tuffaha  4 , Daniel A Galvão  2 , Peter Heathcote  5 , Manish I Patel  6 , David Christie  7   8 , Sam Egger  3 , Sally Am Sara  9 , Nicole Heneka  10 , Suzanne K Chambers  11 , Jeff Dunn  10   9
Affiliations

Prostate Cancer Survivorship Essentials for men with prostate cancer on androgen deprivation therapy: protocol for a randomised controlled trial of a tele-based nurse-led survivorship care intervention (PCEssentials Hormone Therapy Study)

Anna Green et al. BMJ Open. .

Abstract

Introduction: Androgen deprivation therapy (ADT) is commonly used to treat men with locally advanced or metastatic prostate cancer. Men receiving ADT experience numerous side effects and frequently report unmet supportive care needs. An essential part of quality cancer care is survivorship care. To date, an optimal effective approach to survivorship care for men with prostate cancer on ADT has not been described. This protocol describes a randomised trial of tele-based nurse-led survivorship that addresses this knowledge gap: (1) determine the effectiveness of a nurse-led survivorship care intervention (PCEssentials), relative to usual care, for improving health-related quality of life (HR-QoL) in men with prostate cancer undergoing ADT and (2) evaluate PCEssentials implementation strategies and outcomes, including cost-effectiveness, compared with usual care.

Methods and analysis: This is an effectiveness-implementation hybrid (type 1) trial with participants randomised to one of two arms: (1) minimally enhanced usual care and (2) nurse-led prostate cancer survivorship essentials (PCEssentials) delivered over four tele-based sessions, with a booster session 5 months after session 1. Eligible participants are Australian men with prostate cancer commencing ADT and expected to be on ADT for a minimum of 12 months. Participants are followed up at 3, 6 and 12 months postrecruitment. Primary outcomes are HR-QoL and self-efficacy. Secondary outcomes are psychological distress, insomnia, fatigue and physical activity. A concurrent process evaluation with participants and study stakeholders will be undertaken to determine effectiveness of delivery of PCEssentials.

Ethics and dissemination: Ethics approval was obtained from the Metro South Health HREC (HREC/2021/QMS/79429). All participants are required to provide written informed consent. Outcomes of this trial will be published in peer-reviewed journals. The findings will be presented at conferences and meetings, local hospital departments, participating organisations/clinical services, and university seminars, and communicated at community and consumer-led forums.

Trial registration number: ACTRN12622000025730.

Keywords: health education; nursing Care; prostatic neoplasms; quality of life; randomized controlled trial.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Prostate Cancer Survivorship Essentials Framework.
Figure 2
Figure 2
Study diagram.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Australian Institute of Health and Welfare . Cancer data in Australia. 2023. Available: https://www.aihw.gov.au/reports/cancer/cancer-data-in-australia/contents...
    1. Ralph N, Ng SK, Zajdlewicz L, et al. . Ten-year quality of life outcomes in men with prostate cancer. Psychooncology 2020;29:444–9. 10.1002/pon.5255 - DOI - PubMed
    1. Chipperfield K, Fletcher J, Millar J, et al. . Predictors of depression, anxiety and quality of life in patients with prostate cancer receiving androgen deprivation therapy. Psychooncology 2013;22:2169–76. 10.1002/pon.3269 - DOI - PubMed
    1. Nguyen C, Lairson DR, Swartz MD, et al. . Risks of major long-term side effects associated with androgen-deprivation therapy in men with prostate cancer. Pharmacotherapy 2018;38:999–1009. 10.1002/phar.2168 - DOI - PubMed
    1. Mazariego CG, Egger S, King MT, et al. . Fifteen year quality of life outcomes in men with Localised prostate cancer: population based Australian prospective study. BMJ 2020;371:m3503. 10.1136/bmj.m3503 - DOI - PMC - PubMed

Publication types